A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer.
A phase-II randomized trial has been undertaken in 49 patients with operable lung cancer, to determine the effect of a single IV infusion of killed C. parvum vaccine as an adjuvant to surgery. The number of patients was insufficient to provide a decisive result, but analysis 6 years after the last patient was admitted shows that the adjuvant therapy certainly did not shorten, and may well have prolonged, survival. Of the patients with squamous cell carcinoma who were alive 1 year after operation all except one in the C. parvum-treated group were alive 4 years later, whereas five in the control group died during this interval. Judgement concerning the value of IV administration of CP as adjuvant therapy in patients with operable lung cancer should be deferred until further evidence is available.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000601:surgery / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D011425:Propionibacterium acnes / Q000276:immunology*; D012606:Scotland
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines